Kommuniké från årsstämma i Coegin Pharma AB (publ)

Coegin Pharma AB (publ) publicerar delårsrapport för första kvartalet 2022

Coegin Pharma beslutar om offensiv strategisk plan för 2022/2023

Coegin Pharma inleder utlicensieringsprocess av det förvärvade projektet för stimulering av hårväxt

Coegin Pharma rekryterar erfaren Chief Medical Officer

Coegin Pharma offentliggör årsredovisning för 2021

Coegin Pharma tar nästa strategiska steg i det kliniska utvecklingsprogrammet för AVX001 inom hudcancer

Kallelse till årsstämma i Coegin Pharma AB (publ)

BioStock publicerar artikel om Coegin Pharmas avslutade fas l/ll-studie inom aktinisk keratos

Coegin Pharma rapporterar positiva top-line data från COAK-studien, en klinisk fas I/II studie med AVX001 inom aktinisk keratos

Coegin Pharma, a Nordic biotechnology company that, with unique technologies and competencies, develops novel treatments in cancer and inflammatory-driven diseases today reports positive top-line data from its COAK study - a clinical Phase I/II trial in which the safety and tolerability of AVX001 was evaluated in 60 patients with actinic keratosis. The findings demonstrated that two different doses of AVX001 (1% and 3%) are safe and well tolerated in treatment of patients with actinic keratosis. While the study was not designed to draw definite conclusions on efficacy, the findings indicate a clear tendency to efficacy and a potential for AVX001 to become a future treatment option for patients with actinic keratosis. Based on these results, additional in-depth analyses of the findings from the study are ongoing in parallel with the evaluation and planning of the continued clinical development of AVX001.

Coegin Pharma reports positive top-line results from the COAK study, a clinical Phase I/II trial with AVX001 in actinic keratosis

Coegin Pharma, a Nordic biotechnology company that, with unique technologies and competencies, develops novel treatments in cancer and inflammatory-driven diseases today reports positive top-line data from its COAK study - a clinical Phase I/II trial in which the safety and tolerability of AVX001 was evaluated in 60 patients with actinic keratosis. The findings demonstrated that two different doses of AVX001 (1% and 3%) are safe and well tolerated in treatment of patients with actinic keratosis. While the study was not designed to draw definite conclusions on efficacy, the findings indicate a clear tendency to efficacy and a potential for AVX001 to become a future treatment option for patients with actinic keratosis. Based on these results, additional in-depth analyses of the findings from the study are ongoing in parallel with the evaluation and planning of the continued clinical development of AVX001.